Isha Mol

5PUBLICATIONS
5CO-AUTHORS
ElectrometallurgyRespiratory diseasesGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 19, 2025
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results.

Isha Mol, Yannan Hu, Thomas W LeBlanc

|Apr 14, 2025
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Bhavesh Shah, Rickard Sandin, Yun Liu

|Apr 07, 2025
Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison.

Isha Mol, Yannan Hu, Thomas W LeBlanc

|Feb 13, 2024
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.

Isha Mol, Yannan Hu, Thomas W LeBlanc

|Dec 11, 2023
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.

Isha Mol, Yannan Hu, Thomas W LeBlanc

Pageof 1

Frequent Collaborators

3 joint publications

Thomas W LeBlanc

3 joint publications

Haitao Chu

2 joint publications

Alex Schepart

1 joint publications

Yun Liu